| Pharmacokinetic parameters |
Drug suspension |
Marketed Tablet formulation |
SNEEDS |
| Tmax(h) |
2 |
2 |
1 |
| Ke |
0.08095 ± 0.0266 |
0.0957 ± 0.0153 |
0.115 ± 0.0162 |
| Cmax(ng/ml) |
56.42 ± 1.89 |
60.65 ± 2.13 |
80.25 ± 2.34**## |
| T1/2(h) |
8.56 ± 0.21 |
7.242 ± 0.15 |
6.026 ± 0.18**## |
| AUMC0-t(ng h/ml) |
31417.76 ± 1920 |
49855.41 ± 1860 |
75655.37 ± 2410**## |
| AUMC0-∞ (ng h/ml) |
149156.8088 ± 490 |
218219.4643 ± 530 |
276444.5874 ± 610**## |
| AUC0-t(ng h/ml) |
473.22 ± 35.52 |
550.71 ± 42.56* |
691.3738 ± 68.9**## |
| AUC0-∞(ng h/ml) |
738.527 ± 72.5 |
861.99 ± 21.6 |
971.199 ± 59.35**## |
| Fr |
---- |
1.3 |
1.6 |
| Fr |
---- |
---- |
1.2 |
| MRT(h) |
201.965 |
253.158 |
284.642 |
Values are expressed as mean ± S.D; n=2
*P<0.05; **P< 0.01;***P<0.001 when compared with pure drug
#P<0.05; ##P<0.01 when compared with conventional formulation
One way ANOVA followed by TUKEY-KRAMERS multiple comparision test. |
